- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04462393
Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19
Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19 During the First 60 Days of the 2020 Pandemic
This is a registry-based cohort study of all adult patients (≥18 years) admitted to Swedish Intensive Care Units with confirmed SARS-CoV-2 infection and COVID-19 disease during the first 2 months of the 2020 pandemic.
The main goal is to describe demographic characteristics, coexisting conditions, treatments and outcomes among critically ill patients with COVID-19. A secondary goal is to identify independent risk factors associated with increased mortality for these patients.
Data regarding baseline characteristics including comorbidities, intensive care treatments and outcomes will be extracted. ICU lengths of stay and 30-day mortalities will be calculated. The primary outcome is 30-day all-cause mortality. THIS PART OF THE STUDY HAS BEEN COMPLETED.
UPDATE 26 Feb 2022:
Characteristics and outcomes of 'first wave' patients admitted to Swedish ICUs was published in Eur J Anaesthesiol. 2021 Apr 1;38(4):335-343. doi: 10.1097/EJA.0000000000001459.
A description of the surge response and aggregated data outcomes in Scandinavian countries was published in https://onlinelibrary.wiley.com/doi/10.1111/aas.13983.
ADDITIONAL SUMMARY - EXTENDED INCLUSION PERIOD AND ADDITION OF LONG-TERM OUTCOMES Due to the continued influx of patients requiring intensive care throughout 2020 and 2021, we extended the inclusion period to 30 June 2021. Thus this new cohort will include all patients admitted to ICUs in Sweden from 6 March 2020 to 30 June 2021.
We will investigate short (30day mortality) and long-term outcomes (365d mortality and cardiovascular complications) of patients admitted to Swedish ICUs with confirmed SARS-CoV-2 infection and COVID-19 disease.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Previous studies reporting outcomes for COVID-19 patients admitted to intensive care units (ICUs) have been hampered by right-censoring after short observation periods. None have reported 30-day mortality rates and the vast majority of studies have substantial proportions of undischarged patients at the time of follow-up. The lack of follow-up at least to ICU discharge may cause bias in reported mortality rates. Further, national data on critically ill patients have not been previously published.
UPDATE 26 Feb 2022: A number of large, cohort studies including national population outcomes have now been published.
This is a registry-based cohort study of all adult patients (≥18 years) admitted to Swedish Intensive Care Units with confirmed SARS-CoV-2 infection and COVID-19 disease during the first 2 months of the 2020 pandemic. The Swedish Intensive Care Registry (SIR) collects data on patients admitted to all Swedish ICUs, with 100% coverage since 2019. Thus, SIR is able to report on outcomes in a national intensive care population without selection. Little is known about the epidemiology of COVID-19 infections in Sweden, which has one of the world's highest life expectancies and a significant burden of comorbidity. Coupled with Sweden's 'relaxed' approach to COVID-19 pandemic management, health care outcomes are understandably under question.
The main goal is to describe demographic characteristics, coexisting conditions, treatments and outcomes among critically ill patients with COVID-19. A secondary goal is to identify independent risk factors associated with increased mortality for these patients.
ADDITIONAL SUMMARY updated 20 October 2021 Due to the continued influx of COVID-19 patients in ICUs in Sweden throughout 2020 and 2021, we extended of our sample size to encompass all patients admitted up to 30 June 2021 (previously 6 May 2020).
We aim to investigate short- and long-term outcomes including mortality and the incidence of new cardiovascular and respiratory diagnoses up to one year after inclusion.
On 22 mar 2021 we received ethical committee approval for these extensions.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Locais de estudo
-
-
Östergötland
-
Linköping, Östergötland, Suécia, 50185
- Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Östergötland
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adult patients (≥18 years)
admitted to Swedish Intensive Care Units with confirmed SARS-CoV-2 infection and COVID-19 disease during the first 2 months of the 2020 pandemic (6 March-6May2020).
Descrição
Inclusion Criteria:
- Adult patients (≥18 years)
- COVID-19 disease
Exclusion Criteria:
- No Swedish personal identity number
- 'Opt out' from Swedish Intensive Care Registry
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Retrospectivo
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
30-day mortality
Prazo: 30 days
|
all-cause
|
30 days
|
365-day mortality
Prazo: 365 days (additional outcome added Oct 2021 after additional approval from ethical committee)
|
all-cause
|
365 days (additional outcome added Oct 2021 after additional approval from ethical committee)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
ICU mortality
Prazo: 30 days
|
all cause
|
30 days
|
Morbidity
Prazo: up to 365 days after study inclusion
|
Cardiovascular and Respiratory Diseases
|
up to 365 days after study inclusion
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SweCOVID
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em COVID-19
-
Yang I. PachankisAtivo, não recrutandoInfecção Respiratória COVID-19 | Síndrome de Estresse COVID-19 | Reação adversa à vacina COVID-19 | Tromboembolismo associado à COVID-19 | Síndrome Pós-Cuidados Intensivos COVID-19 | AVC associado à COVID-19China
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...ConcluídoSequelas pós-agudas de COVID-19 | Condição pós-COVID-19 | Longo-COVID | Síndrome COVID-19 CrônicaItália
-
Massachusetts General HospitalRecrutamentoSíndrome pós-aguda de COVID-19 | Longo COVID | Sequelas pós-agudas de COVID-19 | Longo COVID-19Estados Unidos
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkAinda não está recrutandoSíndrome pós-COVID-19 | Longo COVID | Longo Covid19 | Condição pós-COVID-19 | Síndrome pós-COVID | Condição pós-COVID-19, não especificada | Condição Pós-COVIDHolanda
-
Indonesia UniversityRecrutamentoSíndrome pós-COVID-19 | Longo COVID | Condição pós-COVID-19 | Síndrome pós-COVID | Longo COVID-19Indonésia
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... e outros colaboradoresRecrutamentoCOVID-19 | Síndrome pós-COVID-19 | Pós-Agudo COVID-19 | COVID-19 agudoChina
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyConcluídoSíndrome pós-COVID-19 | Síndrome de Longo-COVID-19Alemanha
-
Medisch Spectrum TwenteZiekenhuisgroep Twente; University of TwenteAtivo, não recrutando
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecrutamentoPneumonia COVID-19 | Infecção Respiratória COVID-19 | Pandemia do covid-19 | Síndrome do Desconforto Respiratório Agudo COVID-19 | Pneumonia associada à COVID-19 | Coagulopatia Associada à COVID 19 | COVID-19 (doença de coronavírus 2019) | Tromboembolismo associado à COVID-19Grécia
Ensaios clínicos em Admission to ICU for COVID-19
-
AstraZenecaConcluído
-
Hasanuddin UniversityChulalongkorn UniversityConcluído
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...ConcluídoContágio do coronavírusFrança
-
University of PennsylvaniaPublic Health Management CorporationConcluído
-
University of PennsylvaniaPublic Health Management CorporationConcluído
-
AstraZenecaConcluído
-
Kanuni Sultan Suleyman Training and Research HospitalAyşegül Bestel; İbrahim Polat; Merve Aldıkaçtıoğlu TalmaçConcluídoDepressão, Pós-parto | Ansiedade | COVIDPeru
-
Assaf-Harofeh Medical CenterConcluído
-
Istituto Ortopedico GaleazziDesconhecidoCovid19 | Fratura de fêmur | Fratura por FragilidadeItália
-
University of AberdeenAinda não está recrutandoCovid19 | Embolia pulmonar